Boccardo P, Soregaroli M, Aiello S, Noris M, Donadelli R, Lojacono A, Benigni A
Mario Negri Institute for Pharmacological Research, Bergamo, Italy.
Br J Obstet Gynaecol. 1996 Sep;103(9):879-86. doi: 10.1111/j.1471-0528.1996.tb09906.x.
To investigate systemic and fetal-placental nitric oxide synthesis by biochemical and molecular biology means in normal human pregnancy and pre-eclampsia.
Three groups of women were studied: healthy pregnant women (n = 8), pregnant women with pre-eclampsia (n = 8), and age-matched nonpregnant controls (n = 8). Pre-eclamptic patients were treated with nifedipine (30-60 mg/day) for severe hypertension. Systemic nitric oxide synthesis was assessed in normal pregnant women at weeks 18-21, 29-32 and 38-39 and in pre-eclamptic women on admission to the hospital (29-32 weeks, 30 on average), before the morning nifedipine administration. Nonpregnant women were studied twice at four-week intervals as controls. The pattern of nitric oxide biosynthesis in fetal-placental circulation was studied in normal and pre-eclamptic women at the delivery.
Mario Negri Institute for Pharmacological Research, Bergamo, and the Division of Obstetrics and Gynaecology of the University of Brescia.
Plasma cGMP levels and platelet nitric oxide synthesis, assessed by measuring the conversion of [3H]L-arginine to [3H]L-citrulline as well as intracellular cGMP, were evaluated. Constitutive nitric oxide synthase (EC-NOS) gene expression by Northern blot analysis and nitric oxide release by the conversion of [3H]L-arginine to [3H]L-citrulline were assessed in umbilical vein endothelial cells (HUVEC) and in placenta. Inducible nitric oxide synthase activity was also evaluated in HUVEC exposed to tumour necrosis factor alpha (TNF alpha) and in placenta homogenates incubated in calcium free medium.
Plasma cGMP was higher in both normal pregnant and pre-eclamptic women than in nonpregnant controls. In normal pregnancy cGMP rose as early as 18-21 weeks and remained elevated throughout pregnancy. [3H]L-citrulline production and intracellular cGMP were comparable in platelets from all women. EC-NOS gene expression and nitric oxide synthesis were identical in HUVEC and placenta from normal pregnant and pre-eclamptic women.
Systemic levels of CGMP, the nitric oxide second messenger, are increased in normal pregnancy. Excessive nitric oxide production does not derive from platelets. Pre-eclampsia is not associated with changes in fetal-placental nitric oxide synthesis.
采用生化及分子生物学方法,研究正常妊娠及子痫前期患者体内及胎儿 - 胎盘一氧化氮的合成情况。
研究对象分为三组:健康孕妇(n = 8)、子痫前期孕妇(n = 8)以及年龄匹配的非孕对照者(n = 8)。子痫前期患者因重度高血压接受硝苯地平治疗(30 - 60毫克/天)。在妊娠18 - 21周、29 - 32周及38 - 39周时评估正常孕妇的全身一氧化氮合成情况,在子痫前期孕妇入院时(平均孕周29 - 32周)且在早晨服用硝苯地平之前进行评估。非孕女性作为对照,每隔四周研究两次。在分娩时研究正常及子痫前期孕妇胎儿 - 胎盘循环中一氧化氮生物合成的模式。
贝加莫马里奥·内格里药理研究所及布雷西亚大学妇产科。
评估血浆环磷酸鸟苷(cGMP)水平及血小板一氧化氮合成情况,通过测量[3H]L - 精氨酸向[3H]L - 瓜氨酸的转化以及细胞内cGMP来进行评估。采用Northern印迹分析法评估组成型一氧化氮合酶(EC - NOS)基因表达情况,并在脐静脉内皮细胞(HUVEC)及胎盘中通过测量[3H]L - 精氨酸向[3H]L - 瓜氨酸的转化来评估一氧化氮释放情况。还在暴露于肿瘤坏死因子α(TNFα)的HUVEC及在无钙培养基中孵育的胎盘匀浆中评估诱导型一氧化氮合酶活性。
正常孕妇及子痫前期孕妇的血浆cGMP水平均高于非孕对照者。在正常妊娠中,cGMP早在18 - 21周时就升高,并在整个孕期保持升高。所有女性血小板中[3H]L - 瓜氨酸的生成及细胞内cGMP水平相当。正常孕妇及子痫前期孕妇的HUVEC及胎盘中EC - NOS基因表达及一氧化氮合成情况相同。
正常妊娠时,一氧化氮第二信使cGMP的全身水平升高。一氧化氮的过量产生并非源于血小板。子痫前期与胎儿 - 胎盘一氧化氮合成的变化无关。